Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $1.35B |
| Gross Profit (TTM) | $802.16M |
| EBITDA | $358.79M |
| Operating Margin | 17.90% |
| Return on Equity | 11.20% |
| Return on Assets | 6.60% |
| Revenue/Share (TTM) | $29.08 |
| Book Value | $18.41 |
| Price-to-Book | 5.59 |
| Price-to-Sales (TTM) | 3.46 |
| EV/Revenue | 4.164 |
| EV/EBITDA | 20.82 |
| Quarterly Earnings Growth (YoY) | 2.90% |
| Quarterly Revenue Growth (YoY) | 5.60% |
| Shares Outstanding | $45.50M |
| Float | $44.89M |
| % Insiders | 1.26% |
| % Institutions | 112.60% |
Volatility is currently contracting
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.
Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago.
Financial release and supplemental presentation accessible online BOSTON, Aug. 6, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2027, which ended June 27, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HAE and any ticker you trade — then tracks every position and per-strategy win rate.
